GLOBAL INVESTOR STATEMENT IN SUPPORT OF AN EFFECTIVE, FAIR AND EQUITABLE GLOBAL RESPONSE TO COVID-19

As of 23 February 2021, this statement has already been signed by 148 institutional investors and their representatives with over USD \$14 trillion in assets under management or advice. The statement is still open for signature.

As institutional investors with millions of beneficiaries around the world, we recognise and attach considerable importance to the need for an effective, fair and equitable global response to COVID-19. For this reason, we are concerned about the negative impact that limited funding for the Access to COVID-19 Tools (ACT) Accelerator and uneven global access to health technologies (from vaccines and monoclonal antibodies to diagnostics and medical oxygen) will have on the trajectory of the pandemic and global economic activity in the coming years.

A <u>study</u> commissioned by the International Chamber of Commerce Research Foundation has found that advanced economies that can vaccinate all of their citizens remain at risk of a sluggish recovery with a drag on GDP if infection continues to spread unabated in emerging markets. In fact, the global economy stands to lose as much as US\$ 9.2 trillion if governments fail to ensure that developing economies gain access to COVID-19 vaccines. These losses dwarf the funding needed to enable vaccines to be procured for everyone, everywhere – making a clear "investment case" for full capitalization of the ACT-Accelerator and a coordinated global approach to distribution.

A different <u>study</u> commissioned by the Bill & Melinda Gates Foundation has reached a similar conclusion: leaving lower-income countries without access to vaccines amid the COVID-19 pandemic will cause significant economic damage that puts decades of economic progress at risk – for both emerging markets and advanced economies alike. The report has estimated that the economic benefits of a global equitable vaccine solution alone for the 10 countries included in the analysis would be at least US\$ 153 billion in 2020-21, rising to US\$ 466 billion by 2025. This is more than 12 times the US\$ 38 billion estimated total cost of the ACT-Accelerator.

Given the pervasive health and social costs of the pandemic, we recognise a strong moral argument to leave no one behind. The two reports above highlight that empowering an effective, fair and equitable global response to COVID-19 via the ACT-Accelerator in 2021 is not only the right thing to do – it also makes full economic sense. We therefore:

- a) Encourage world leaders in the G7, G20 and ACT-Accelerator Facilitation Council to finance the ACT-Accelerator in full and deploy adequate funding to ensure fair and equitable access to COVID-19 tools globally;
- b) Commit to work with the <u>Access to Medicine Foundation</u> on this issue and engage (bilaterally and/or via existing collaborative initiatives) with our investee healthcare companies to promote industry actions supporting the mission and operations of the ACT-Accelerator (e.g., cross-industry partnerships to accelerate R&D and expand production, equitable pricing strategies, voluntary licensing agreements); and
- c) Recommend that governments and international organisations explore the feasibility of innovative finance mechanisms for national and global COVID-19 responses, similar to <u>vaccine bonds</u> issued by the International Finance Facility for Immunisation or <u>social bonds for COVID-19 programmes</u> issued by individual or multiple governments. These mechanisms could build on the strong response by capital markets to ESG-labelled debt issued in 2020.

The International Monetary Fund <u>has urged</u> the international community to act quickly to make sure that COVID-19 health technologies are available globally to mitigate the risks of virus mutations and address what is currently a deeply iniquitous distribution of COVID-19 tools across the world.

We support this call for action. The time to act is now.

NOTE: The following investor signatories are listed in alphabetical order by organisation name.

a.s.r. asset management

Achmea

ACTIAM

Adrian Dominican Sisters, Portfolio

Advisory Board

Aegon Asset Management

Aegon Netherlands

Aequo

AkademikerPension

Alecta pensionsförsäkring, ömsesidigt

Align Impact
AllianceBernstein

Alquity Investment Management

Limited

American Century Investments

AMP Capital

AP7 (Sjunde AP-fonden)

ASN Beleggingsfondsen Asset Management One

Australian Ethical Investment

Avaron Asset Management Aviva Investors

Aware Super

AXA Investment Managers
Baloise Asset Management
BanSabadell Pensiones E.G.F.P., S.A.
BANSABADELL PENTAPENSION

EMPRESA FP

BBVA Asset Management

Joh. Berenberg, Gossler & Co. KG

(Berenberg)

BlueBay Asset Management

BMO Global Asset Management Bon Secours Mercy Health

Boston Common Asset Management

Boston Trust Walden

CANDRIAM

Castlefield Investment Partners Central Finance Board of the

Methodist Church Church of Sweden

The Church Pension Fund (Finland)

ClearBridge Investments

Coho Partners

Columbia Threadneedle

Comgest

CommonSpirit Health

Compañía de servicios de bebidas refrescantes pensiones, F.P Congregation of St. Joseph

Coöperatie VGZ U.A.

The Dai-ichi Life Insurance Company,

Limited

Dana Investment Advisors

Daughters of Charity, Province of St.

Louise

DNB Asset Management

Domini Impact Investments LLC

EFG Asset Management

Egamo

EOS at Federated Hermes

Ethical Partners Funds Management

Everence and the Praxis Mutual Funds

Fidelity International The Folksam Group

Fondo de Pensiones de los Empleados

de Banco Sabadell GM

Fondo de Pensiones de los Empleados

de Banco Sabadell MF2000 Forum Equity Partners

Future Super GAM Investments

Genesis Investment Management

GMO

De Goudse Verzekeringen Groupama Asset Management

HESTA Hexavest ICCR

Impact Investors

Impax Asset Management | Pax World

Funds

Indecap Fonder AB
Insight Investment

ISGAM

Jlens Investor Network

Jupiter Asset Management

KBI Global Investors

Kempen Capital Management
KLP Kapitalforvaltning AS

Länsförsäkringar Liv AB

La Banque Postale Asset Management

La Financière de l'Echiquier Liontrust Asset Management PLC

Local Government Super London LGPS CIV Ltd M&G Investments Man Group plc

 ${\sf MediRisk}$

Mercy Investment Services, Inc.

Midat Cyclops FP

Miller/Howard Investments

Mirova

Montanaro Asset Management Mutualitat dels Enginyers MPS NEI Investments

Newground Social Investment NN Investment Partners Nomura Asset Management Nordea Asset Management

Northwest Coalition for Responsible

Investment

OFI Asset Management

Öhman

Parnassus Investments
Providence Capital NV
RAM Active Investments SA
Rathbone Greenbank Investments
Reynders, McVeigh Capital
Management, LLC

Robeco

San Francisco Employees' Retirement

System (SFERS) Schroders

SEB Investment Management AB

Shareholders for Change

The Sisters of St Francis of Philadelphia The Socially Responsible Investing Group of 1919 Investment Counsel

Statewide Super Stewart Investors

Stichting Algemeen Pensioenfonds

Stap

Stichting Pensioenfonds Huisartsen Stichting Pensioenfonds Medisch

Specialisten Storebrand

Sumitomo Mitsui Trust Asset

Management

Sycomore Asset Management

The Maryknoll Sisters
Trillium Asset Management

Trinity Health

Triodos Investment Management

Trusteam Finance
Tundra Fonder
Unipol Group
United Church Funds

The United Church of Canada USS Investment Management Vancity Investment Management

Verve Super VvAA Groep

Wespath Benefits and Investments

WHEB Asset Management
Zevin Asset Management